The Feasibility Study Of Application Of Semi-tirofiban In Selective Percutaneous Coronary Intervention In Patients With Acute Coronary Syndrome

Objective: To investigate the safety and efficacy of decrement of tirofiban in patients with Acute Coronary Syndrome(ACS)selective percutaneous coronary intervention(PCI).Method: A total of 173 ACS patients who accepted selective PCI treatment were enrolled from February 2017 to November 2017 at the Cardiology Departmemt of the Second Hospital of Hebei Medical University in this study.According to the application of tirofiban,patients were divided into tirofiban group and no tirofiban group.The two groups of patients were given aspirin,clopidogrel and low molecular weight heparin treatment before PCI.On the basis,patients of the tirofiban groups were given semi-Tirofiban Hydrochloride Injection treatment.TIMI grading,TMPG grading,PLT before and after PCI were compared between the two groups.The bleeding events and MACE events during the hospitalization were recorded in two groups.Results: There were no significant differences in TIMI grading,TMPG grading and PLT before and after PCI between two groups(P > 0.05).There were no significant differences in blood glucose,serum potassium,total cholesterol,low density lipoprotein cholesterol,creatinine,platelet count,white blood cell count,hsCRP,APTT and the rate of platelet aggregation in Two groups(P > 0.05).The rates of TIMI3 and TMPG3 in the tirofiban group had higher tendencies than those in the no tirofiban group after operation.The incidence of the main MACE events in tirofiban group was lower than that of the no tirofiban group,but no statistical difference.Conclusion:To some extent,semi-Tirofiban can reduce ischemic events in patients with acute coronary syndrome treated with selective PCI and no increase the incidence of bleeding.